secwatch.observer — SEC 8-K summary
======================================

Issuer:     Neurogene Inc. (NGNE)
CIK:        0001404644
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001628280-23-007026
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Neoleukin initiates strategic alternatives review, cuts workforce by 70%, CEO Drachman to step down
--------------------------------------------------------------------------------

- Engaged SVB Securities to explore sale, merger, asset divestiture, licensing, or other transaction to maximize shareholder value.
- Board approved 70% workforce reduction to preserve cash; completion expected in first half of 2023.
- CEO Jonathan Drachman, M.D., stepping down after a short transition period.
- No assurance that any transaction will occur or on attractive terms; company will not disclose updates until definitive agreements reached.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/0001628280-23-007026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404644/000162828023007026/nltx-20230308.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-007026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer